Alluvi, known as BI 4744, represents a promising development in obesity care. This dual activator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide targets demonstrates remarkable efficacy in https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/